Kristen Coppock, MA, Managing Editor

Patients with the coronavirus disease 2019 (COVID-19) are filling more than half of the ICU beds in 40% of the hospitals represented in the survey.

Remdesivir is not approved by the FDA. However, EUA allows for distribution and emergency use for treatment of COVID-19.

Remdesivir is not approved by the FDA nor licensed or approved anywhere in the world.

The era of social distancing will likely leave a lasting impression on telehealth services, as HCPs quickly learn to incorporate it as a valuable tool and adapt to changes.

During the COVID-19 pandemic, pharmacists are concerned not only about shortages in drugs that could treat the virus, but also medications for managing other conditions.

These professional organizations are aware that some medications are being prophylactically prescribed as potential treatments for COVID-19.

The EUA designation allows the test to be used to detect SARS-CoV-2, the virus that causes COVID-19, for the duration of the continuing pandemic.

Not enough people are taking seriously frequent recommendations to practice social distancing, he said.

The COVID-19 High Performance Computing Consortium is a partnership of federal government, tech industry, and academic leaders whose goal is to stop the virus.

Steven C. Hoffart, PharmD, owner and operator of Magnolia Pharmacy in Magnolia, Texas, said his pharmacy had run out of prepared hand sanitizer when he saw a need for many people in his area.

The 12 groups represent practice settings of nearly all pharmacists in the United States.

Chloroquine and remdesivir are not FDA-approved for a COVID-19 indications.

The American Pharmacists Association (APhA) is calling upon the federal Coronavirus Task Force to make greater use of pharmacists in combating the novel coronavirus (COVID-19) outbreak.

The availability of personal protective equipment, including face masks, gloves and hand sanitizers, have been a concern to many pharmacists.

The FDA acknowledged that protocol modifications or deviations may be required for clinical trials during the COVID-19 pandemic.

The goals of the expansion are to maintain social distancing and to avoid overburdening hospitals with patients.

Aimmune’s peanut allergen power was approved by the FDA as an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.

The Clinical Advisor program detects potential issues with antibiotic prescribing and sends near real-time alerts to health care providers through means that include mobile devices.

This medication is the first precision therapy approved to treat a genomically defined population of patients with GIST, according to Blueprint Medicines.

Pharmacy professionals with the Practice Advancement Initiative (PAI) 2030 have instituted 59 recommendations to promote optimal, safe, and effective medication use, expand pharmacist and technician roles, and implement the latest technologies.

Population migration to more urban locales, and rural hospital closures are some factors increasing the challenges of health care access to patients and pharmacists in remote areas of the country. Innovation advocated by the National Rural Health Association (NRHA) may provide keys to improving access to health care services.

The FDA has approved cenobamate tablets (XCOPRI, SK Life Sciences) for treatment of partial-onset seizures in adults.

Texas oncologist Stephen Hahn, MD, is expected to receive the Trump administration’s nomination for the role of FDA Commissioner, a move that had been anticipated by federal insiders.

Four pharmaceutical distributors have agreed to settle federal litigation related to the ongoing opioid epidemic for a collective $260 million, less than a day before a federal trial was set to begin in Ohio.

Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.